Li Gong1, Haiming Ding1, Nicholas E Long2,3, Brandon J Sullivan2, Edward W Martin4, Thomas J Magliery2, Michael F Tweedle5. 1. Department of Radiology, The Wright Center for Innovation in Biomedical Imaging, The Ohio State University, Columbus, OH, USA. 2. Department of Chemistry & Biochemistry, The Ohio State University, Columbus, OH, USA. 3. Ohio State Biochemistry Program, The Ohio State University, Columbus, OH, USA. 4. Department of Surgery, The Ohio State University, Columbus, OH, USA. 5. Department of Radiology, The Wright Center for Innovation in Biomedical Imaging, The Ohio State University, Columbus, OH, USA. michael.tweedle@osumc.edu.
Abstract
PURPOSE: Optical surgical navigation (OSN) will be a potent tool to help surgeons more accurately and efficiently remove tumors. The purpose of this study was to evaluate a novel humanized 3E8 antibody (3E8 MAb) fragment site-specifically conjugated with IR800, 3E8.scFv.Cys-IR800, as a potential OSN agent to target colorectal adenocarcinoma. PROCEDURES: An engineered single-chain variable fragment of 3E8 MAb (targeted to TAG-72), appending a C-terminal cysteine residue (3E8.scFv.Cys), was created and reacted with IRDye800-maleimide. 3E8.scFv.Cys-IR800 identity and purity were verified by MALDI-TOF mass spectra and 800 nm detected size exclusion column HPLC. In vitro human colon adenocarcinoma LS-174 T cells binding and competition assay validated biological functionality. We further evaluated the imaging ability and receptor-specific binding of 3E8.scFv.Cys-IR800 in an orthotopic LS-174 T mouse model. RESULTS: A 1:1 dye to protein conjugate was achieved at greater than 90 % HPLC purity. A 1 nmol dose of 3E8.scFv.Cys-IR800 via intraperitoneal injection administration was sufficient to produce high tumor to background fluorescence contrast. Blocking competition studies both in vitro and in vivo using a different blocking protein, 3E8ΔCH2, demonstrated 3E8.scFv.Cys-IR800 binding specificity for TAG-72 antigen. CONCLUSIONS: 3E8.scFv.Cys-IR800 shows properties useful in a clinically viable OSN agent for colorectal cancer.
PURPOSE: Optical surgical navigation (OSN) will be a potent tool to help surgeons more accurately and efficiently remove tumors. The purpose of this study was to evaluate a novel humanized 3E8 antibody (3E8 MAb) fragment site-specifically conjugated with IR800, 3E8.scFv.Cys-IR800, as a potential OSN agent to target colorectal adenocarcinoma. PROCEDURES: An engineered single-chain variable fragment of 3E8 MAb (targeted to TAG-72), appending a C-terminal cysteine residue (3E8.scFv.Cys), was created and reacted with IRDye800-maleimide. 3E8.scFv.Cys-IR800 identity and purity were verified by MALDI-TOF mass spectra and 800 nm detected size exclusion column HPLC. In vitro humancolon adenocarcinoma LS-174 T cells binding and competition assay validated biological functionality. We further evaluated the imaging ability and receptor-specific binding of 3E8.scFv.Cys-IR800 in an orthotopic LS-174 T mouse model. RESULTS: A 1:1 dye to protein conjugate was achieved at greater than 90 % HPLC purity. A 1 nmol dose of 3E8.scFv.Cys-IR800 via intraperitoneal injection administration was sufficient to produce high tumor to background fluorescence contrast. Blocking competition studies both in vitro and in vivo using a different blocking protein, 3E8ΔCH2, demonstrated 3E8.scFv.Cys-IR800 binding specificity for TAG-72 antigen. CONCLUSIONS: 3E8.scFv.Cys-IR800 shows properties useful in a clinically viable OSN agent for colorectal cancer.
Authors: Mark Rijpkema; Wim J Oyen; Desiree Bos; Gerben M Franssen; David M Goldenberg; Otto C Boerman Journal: J Nucl Med Date: 2014-06-30 Impact factor: 10.057
Authors: Martin C Boonstra; Hein W Verspaget; Sjam Ganesh; Frank J G M Kubben; Alexander L Vahrmeijer; Cornelis J H van de Velde; Peter J K Kuppen; Paul H A Quax; Cornelis F M Sier Journal: Curr Pharm Des Date: 2011 Impact factor: 3.116
Authors: Stephen P Povoski; Ryan L Neff; Cathy M Mojzisik; David M O'Malley; George H Hinkle; Nathan C Hall; Douglas A Murrey; Michael V Knopp; Edward W Martin Journal: World J Surg Oncol Date: 2009-01-27 Impact factor: 2.754
Authors: Ju Hee Ryu; Jin Hee Na; Ho Kyung Ko; Dong Gil You; Subin Park; Eunsung Jun; Ho Jun Yeom; Deok Ho Seo; Jae Hyung Park; Seo Young Jeong; In-San Kim; Byung-Soo Kim; Ick Chan Kwon; Kuiwon Choi; Kwangmeyung Kim Journal: Biomaterials Date: 2013-12-18 Impact factor: 12.479
Authors: Jeong Youp Park; Takashi Murakami; Jin Young Lee; Yong Zhang; Robert M Hoffman; Michael Bouvet Journal: PLoS One Date: 2016-01-05 Impact factor: 3.240
Authors: Nicholas E Long; Brandon J Sullivan; Haiming Ding; Stephanie Doll; Michael A Ryan; Charles L Hitchcock; Edward W Martin; Krishan Kumar; Michael F Tweedle; Thomas J Magliery Journal: J Biol Chem Date: 2018-04-18 Impact factor: 5.157
Authors: Ruben D Houvast; Mireille Vankemmelbeke; Lindy G Durrant; Manfred Wuhrer; Victor M Baart; Peter J K Kuppen; Lioe-Fee de Geus-Oei; Alexander L Vahrmeijer; Cornelis F M Sier Journal: Cancers (Basel) Date: 2020-12-21 Impact factor: 6.639
Authors: Thinzar M Lwin; Michael A Turner; Siamak Amirfakhri; Hiroto Nishino; Robert M Hoffman; Michael Bouvet Journal: Cells Date: 2022-01-12 Impact factor: 6.600